GlassScriptPhysician profile
Richard P Zekman
NPI 1043426521
$2,536.07
in general payments reported to CMS, 2019-2025
40 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $689 · 2020: $236 · 2021: $293 · 2022: $813 · 2023: $504.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $425 · Education: $79.28.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $424.67 |
| Education | $79.28 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $280.62 | 2019-2023 | Blincyto |
| Aveo Pharmaceuticals, INC. | $205.39 | 2021-2023 | Fotivda |
| Astrazeneca Pharmaceuticals LP | $202.26 | 2020-2022 | |
| Foundation Medicine, INC. | $160.86 | 2019 | |
| Janssen Biotech, INC. | $147.69 | 2019 | |
| Pfizer INC. | $132.70 | 2019-2023 | |
| Exelixis INC. | $121.54 | 2019 | |
| Seagen INC. | $121.17 | 2021-2023 | Tukysa, Padcev |
| Incyte Corporation | $99.83 | 2019 | |
| Genentech USA, INC. | $96.41 | 2022-2023 | Venclexta |
| Novartis Pharmaceuticals Corporation | $93.50 | 2019-2022 | |
| Genzyme Corporation | $74.65 | 2019-2022 | |
| Celgene Corporation | $68.54 | 2022 | |
| Blueprint Medicines Corporation | $54.99 | 2021 | |
| Merck Sharp & Dohme LLC | $49.65 | 2020-2023 | Keytruda |
Show all 39 companies
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Richard Zekman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.